{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:57:02Z","timestamp":1771667822191,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T00:00:00Z","timestamp":1513036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.diabres.2017.11.027","type":"journal-article","created":{"date-parts":[[2017,11,26]],"date-time":"2017-11-26T16:17:58Z","timestamp":1511713078000},"page":"218-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Original paper: Efficacy and safety analysis of insulin degludec\/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan"],"prefix":"10.1016","volume":"135","author":[{"given":"Mohamed","family":"Hassanein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram Salim","family":"Echtay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Malek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahomed","family":"Omar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shehla Sajid","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Ekelund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadriye","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nor Azmi","family":"Kamaruddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabres.2017.11.027_b0005","unstructured":"Pew Research Center. The future of world religions: population growth projections, 2010\u20132050. [Online] Available at: https:\/\/assets.pewresearch.org\/wp-content\/uploads\/sites\/11\/2015\/03\/PF_15.04.02_ProjectionsFullReport.pdf."},{"key":"10.1016\/j.diabres.2017.11.027_b0010","unstructured":"International Diabetes Federation. Diabetes and Ramadan: practical guidelines. Brussels, Belgium: International Diabetes Federation; 2016. www.idf.org\/guidelines\/diabetes-in-ramadan and www.daralliance.org."},{"key":"10.1016\/j.diabres.2017.11.027_b0015","first-page":"44","article-title":"Trends in global rice consumption","volume":"12","author":"Mohanty","year":"2013","journal-title":"Rice Today"},{"key":"10.1016\/j.diabres.2017.11.027_b0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fpubh.2016.00033","article-title":"Editorial: public health nutrition in the middle east","volume":"4","author":"Hwalla","year":"2016","journal-title":"Front Public Health"},{"key":"10.1016\/j.diabres.2017.11.027_b0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/1947-489X.211054","article-title":"Fasting during the month of Ramadan for people with diabetes: medicine and Fiqh united at last","volume":"1","author":"Beshyah","year":"2009","journal-title":"Ibnosina J Med Biomed Sci"},{"key":"10.1016\/j.diabres.2017.11.027_b0030","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.2337\/diacare.27.10.2306","article-title":"A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries","volume":"27","author":"Salti","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.027_b0035","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/dme.12685","article-title":"Multi-country retrospective observational study of the management and outcomes of patients with Type 2 diabetes during Ramadan in 2010 (CREED)","volume":"32","author":"Babineaux","year":"2015","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2017.11.027_b0040","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.2337\/dc10-0896","article-title":"Recommendations for management of diabetes during Ramadan; update 2010","volume":"33","author":"Al-Arouj","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.027_b0045","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2337\/dc14-0031","article-title":"Insulin analogs\u2013are they worth it? Yes!","volume":"37","author":"Grunberger","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.027_b0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00592-008-0062-7","article-title":"Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan","volume":"46","author":"Bakiner","year":"2009","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.diabres.2017.11.027_b0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diabres.2006.05.012","article-title":"A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting","volume":"75","author":"Cesur","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2017.11.027_b0060","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/j.1464-5491.2009.02836.x","article-title":"Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan","volume":"26","author":"Salti","year":"2009","journal-title":"Diabet Med"},{"key":"10.1016\/j.diabres.2017.11.027_b0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1464-5491.1999.00164.x","article-title":"Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan study group","volume":"16","author":"Akram","year":"1999","journal-title":"Diabetic Med"},{"key":"10.1016\/j.diabres.2017.11.027_b0070","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1742-1241.2010.02347.x","article-title":"Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan","volume":"64","author":"Hui","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2017.11.027_b0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-8227(02)00202-4","article-title":"A comparison of insulin lispro Mix25 and human insulin 30\/70 in the treatment of type 2 diabetes during Ramadan","volume":"59","author":"Mattoo","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2017.11.027_b0080","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/ijcp.12695","article-title":"The Ramadan study G. Effect of a new insulin treatment regimen on glycaemic control and quality of life of Muslim patients with type 2 diabetes mellitus during Ramadan fast \u2013 an open label, controlled, multicentre, cluster randomised study","volume":"69","author":"Shehadeh","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.diabres.2017.11.027_b0085","first-page":"574","article-title":"A multicenter, prospective, non-interventional evaluation of efficacy and safety of using biphasic insulin aspart as monotherapy, or in combination with oral hypoglycemic agent, in the treatment of type 2 diabetic patients before, during, & after Ramadan","volume":"59","author":"Soewondo","year":"2009","journal-title":"J Indonesian Med Ass"},{"key":"10.1016\/j.diabres.2017.11.027_b0090","first-page":"482","article-title":"Treatment of type 1 diabetes with insulin lispro during Ramadan","volume":"27","author":"Kadiri","year":"2001","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.diabres.2017.11.027_b0095","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/BF03347569","article-title":"Insulin therapy during Ramadan fast for Type 1 diabetes patients","volume":"28","author":"Kassem","year":"2005","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.diabres.2017.11.027_b0100","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2337\/diacare.27.5.1209","article-title":"Fasting and insulin glargine in individuals with type 1 diabetes","volume":"27","author":"Mucha","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.027_b0105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/dia.2009.0130","article-title":"Insulin pump therapy in moslem patients with type 1 diabetes during Ramadan fasting: an observational report","volume":"12","author":"Benbarka","year":"2010","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2017.11.027_b0110","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1089\/dia.2012.0061","article-title":"Ramadan fasting in diabetes patients on insulin pump therapy augmented by continuous glucose monitoring: an observational real-life study","volume":"14","author":"Khalil","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.diabres.2017.11.027_b0115","first-page":"29","article-title":"Insulin prescribing practices in Saudi Arabia","volume":"4","author":"Al-shaqha","year":"2015","journal-title":"World J Pharm Pharm Sci"},{"key":"10.1016\/j.diabres.2017.11.027_b0120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.12816\/0001439","article-title":"Management and control of patients with type 2 diabetes mellitus in Lebanon: results from the International Diabetes Management Practices Study (IDMPS)","volume":"61","author":"Azar","year":"2013","journal-title":"Lebanese Med J"},{"key":"10.1016\/j.diabres.2017.11.027_b0125","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2337\/dc08-0435","article-title":"Multifaceted determinants for achieving glycemic control: The International Diabetes Management Practice Study (IDMPS)","volume":"32","author":"Chan","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.027_b0130","unstructured":"Novo Nordisk A\/S. NovoMix 30\u00ae EU SmPC. 2017. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000308\/WC500029441.pdf."},{"key":"10.1016\/j.diabres.2017.11.027_b0135","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.027_b0140","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc13-2908","article-title":"Comparison of insulin degludec\/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial","volume":"37","author":"Fulcher","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2017.11.027_b0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.diabres.2014.09.026","article-title":"Insulin degludec\/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-\/self-mixed insulin: a 26-week, randomised, treat-to-target trial","volume":"107","author":"Kaneko","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2017.11.027_b0150","unstructured":"World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Last amended by the 64th WMA general assembly, Fortaleza; Brazil; 2013. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"key":"10.1016\/j.diabres.2017.11.027_b0155","unstructured":"International Conference on Harmonisation. ICH harmonised tripartite guideline. guideline for good clinical practice; 1996,E6 (R1), Step 4."},{"key":"10.1016\/j.diabres.2017.11.027_b0160","unstructured":"Novo Nordisk A\/S. Ryzodeg\u00ae EU SmPC; 2017. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002499\/WC500139011.pdf."},{"key":"10.1016\/j.diabres.2017.11.027_b0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diabres.2017.03.003","article-title":"Diabetes and Ramadan: practical guidelines","volume":"126","author":"Hassanein","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabres.2017.11.027_b0170","doi-asserted-by":"crossref","unstructured":"International hypoglycaemia study group. Glucose concentrations of less than 3.0 mmol\/L (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care; 2016.","DOI":"10.1007\/s00125-016-4146-6"},{"key":"10.1016\/j.diabres.2017.11.027_b0175","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/1753-0407.12355","article-title":"Lower rates of hypoglycemia during maintenance treatment with insulin degludec\/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two phase 3a studies in type 2 diabetes","volume":"8","author":"Christiansen","year":"2016","journal-title":"J Diabetes"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882271731598X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882271731598X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:08:25Z","timestamp":1759172905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882271731598X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":35,"alternative-id":["S016882271731598X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2017.11.027","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Original paper: Efficacy and safety analysis of insulin degludec\/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2017.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}